Zydus group refutes media report claiming suspension of Biotax sales in Nepal, says will sell antibiotic with 10ml sterile water
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-06-21 06:00 GMT | Update On 2024-06-21 06:00 GMT
New Delhi: Zydus group announced its decision to make available its antibiotic injection Biotax 1g with 10ml sterile water in Nepal, responding to concerns raised by the Department of Drug Administration of Nepal for not providing the solvent. The Indian pharmaceutical group clarified that a media report claiming a suspension of sales and distribution of Biotax 1gm by the Department of Drug Administration, Nepal due to "serious health risks" were misleading and erroneous as it complies with all quality parameters as per approved specification.
"The letter received from the Department of Drug Administration, Nepal, refers to the quantity of sterile water for injection made available with the product," Zydus Group said in a statement.
Zydus has supplied 5ml sterile water for injection along with the product but the direction for use states "use 3ml for intramuscular injection and 10ml for intravenous injection".
"The objection raised by the agency is only with reference to the non-supply of 10ml sterile water for injection along with the product," the statement said, adding that this does not have any impact on product quality nor does it pose any risk to patient safety as stated in the article.
For intramuscular injection, the product can be constituted with 3ml sterile water provided with the product. For intravenous injection, the product should be reconstituted by using 10ml sterile water for injection separately, it added.
Further, it said, "Based on the letter received from DDA Nepal, we are amending as per the agency's requirement, the product will be made available with 10ml sterile water for injection instead of 5ml so that the product can be administered for intramuscular as well as intravenous as per the patient's requirement."
Zydus group asserted that "no product complaint or any adverse event because of the usage of the product has been received from Nepal since the product commercialisation in 2018. The product Biotax 1g injection has been renewed every year as per DDA, Nepal regulation."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd